title: The effect of SLActive surface in guided bone formation in osteoporotic-like conditions.
abstract: OBJECTIVE
  The aim of the study was to evaluate new bone formation under etched titanium (SLA) and modified-etched hydrophilic titanium (modSLA) domes placed on the calvarium of healthy, osteoporotic and osteoporotic treated with bisphosphonates rabbits.
  
  
  METHODS
  Experimental osteoporosis was induced by ovariectomy (OV) and calcium-deficient diet in 24 New Zealand female rabbits. Twelve OV rabbits were treated with weekly dozes of alendronate (Fosamax(®)) (B) while 12 OV rabbits received no treatment (O). Another 12 rabbits were sham operated and used as healthy controls (C). At 6 weeks following OV, one modSLA and one SLA titanium dome were placed in the parietal bones of each rabbit. The animals were sacrificed at 30 and 120 days following the dome placement. Various histomorphometric measurements were performed in the most central of the undecalcified sections produced.
  
  
  RESULTS
  After 30 days of healing, in the C group, the total bone (TB) area was 37.6% and 37.0% under the modSLA and SLA domes, respectively. In the O group, the TB was 35.7% and 24.8%. In the B group, TB was 37.0% and 32.1%, respectively. After 120 days of healing, in the C group TB was 40.1% and 36.4%, respectively. In the O group, TB was 29.6% and 27.9%, respectively. In the B group, TB was 49.7% and 42.5%, respectively. Hierarchical analysis of variance showed that the type of titanium dome significantly influenced new bone and the amount of new bone being in contact with inner surface of the dome (BIC) independently of the observation period and group (P<0.05). The administration of bisphosphonates influenced the BIC (P<0.05).
  
  
  CONCLUSIONS
  The use of modSLA surface may promote bone healing and osseointegration in osteoporotic rabbits, whereas administration of bisphosphonates may compromise the osseointegration of the newly formed bone at the early healing period.
authors.affiliation: Periodontology Unit, Department of Clinical Research, Eastman Dental Institute, University College London, London, UK. n.mardas@eastman.ucl.ac.uk
authors.forename: Nikos
authors.initials: N
authors.lastname: Mardas
authors.forename: Frank
authors.initials: F
authors.lastname: Schwarz
authors.forename: Aviva
authors.initials: A
authors.lastname: Petrie
authors.forename: Ahmad-Reza
authors.initials: AR
authors.lastname: Hakimi
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Donos
mesh_terms: D019386:Alendronate / Q000009:adverse effects*; D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D002118:Calcium / Q000172:deficiency; D005260:Female; D016557:Guided Tissue Regeneration, Periodontal; D057927:Hydrophobic and Hydrophilic Interactions; D020007:Implants, Experimental; D016348:Osseointegration / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010052:Ovariectomy; D010294:Parietal Bone / Q000601:surgery; D011817:Rabbits; D013499:Surface Properties; D013997:Time Factors; D014025:Titanium
chemical_list: D050071:Bone Density Conservation Agents; D014025:Titanium; D002118:Calcium; D019386:Alendronate